This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): anti-CD40L
Description: IDEC-131 is a humanized monoclonal antibody that targets the CD40 ligand on T Cells. T cells interact with and regulate antibody producing B cells through mechanisms that include this cell-surface marker. IDEC-131 functions by binding to CD40 ligand, which reduces the production of antibodies by B cells.
Deal Structure: Eisai will market IDEC-131 in Europe and Asia.
Partners: Eisai Co., Ltd.
Pink Sheet Weekly Trademark Review Jan. 13, 2015
Pink Sheet Weekly Trademark Review Oct. 28, 2014
Pink Sheet Weekly Trademark Review Aug. 26, 2014
Additional information available to subscribers only: